1. Home
  2. PHAR vs PAHC Comparison

PHAR vs PAHC Comparison

Compare PHAR & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • PAHC
  • Stock Information
  • Founded
  • PHAR 1988
  • PAHC 1946
  • Country
  • PHAR Netherlands
  • PAHC United States
  • Employees
  • PHAR N/A
  • PAHC N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • PAHC Biotechnology: Pharmaceutical Preparations
  • Sector
  • PHAR Health Care
  • PAHC Health Care
  • Exchange
  • PHAR Nasdaq
  • PAHC Nasdaq
  • Market Cap
  • PHAR 731.1M
  • PAHC 968.3M
  • IPO Year
  • PHAR N/A
  • PAHC 2014
  • Fundamental
  • Price
  • PHAR $10.39
  • PAHC $30.64
  • Analyst Decision
  • PHAR Strong Buy
  • PAHC Hold
  • Analyst Count
  • PHAR 3
  • PAHC 4
  • Target Price
  • PHAR $30.00
  • PAHC $24.50
  • AVG Volume (30 Days)
  • PHAR 3.7K
  • PAHC 287.9K
  • Earning Date
  • PHAR 07-31-2025
  • PAHC 08-27-2025
  • Dividend Yield
  • PHAR N/A
  • PAHC 1.59%
  • EPS Growth
  • PHAR N/A
  • PAHC 140.17
  • EPS
  • PHAR N/A
  • PAHC 0.78
  • Revenue
  • PHAR $320,708,000.00
  • PAHC $1,190,682,000.00
  • Revenue This Year
  • PHAR $13.31
  • PAHC $28.33
  • Revenue Next Year
  • PHAR $7.68
  • PAHC $13.78
  • P/E Ratio
  • PHAR N/A
  • PAHC $38.67
  • Revenue Growth
  • PHAR 24.13
  • PAHC 19.12
  • 52 Week Low
  • PHAR $6.65
  • PAHC $16.16
  • 52 Week High
  • PHAR $12.61
  • PAHC $30.59
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 47.23
  • PAHC 85.38
  • Support Level
  • PHAR $9.88
  • PAHC $24.59
  • Resistance Level
  • PHAR $10.59
  • PAHC $30.59
  • Average True Range (ATR)
  • PHAR 0.31
  • PAHC 0.86
  • MACD
  • PHAR -0.12
  • PAHC 0.53
  • Stochastic Oscillator
  • PHAR 31.68
  • PAHC 97.92

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Share on Social Networks: